Galderma Group N (GALD) - Net Assets
Based on the latest financial reports, Galderma Group N (GALD) has net assets worth CHF7.73 Billion CHF (≈ $9.77 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF12.88 Billion ≈ $16.28 Billion USD) and total liabilities (CHF5.15 Billion ≈ $6.51 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Galderma Group N (GALD) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF7.73 Billion |
| % of Total Assets | 60.03% |
| Annual Growth Rate | 23.41% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 32.29 |
Galderma Group N - Net Assets Trend (2021–2024)
This chart illustrates how Galderma Group N's net assets have evolved over time, based on quarterly financial data. Also explore Galderma Group N total assets for the complete picture of this company's asset base.
Annual Net Assets for Galderma Group N (2021–2024)
The table below shows the annual net assets of Galderma Group N from 2021 to 2024. For live valuation and market cap data, see market cap of Galderma Group N.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF7.79 Billion ≈ $9.85 Billion |
+72.49% |
| 2023-12-31 | CHF4.52 Billion ≈ $5.71 Billion |
+9.23% |
| 2022-12-31 | CHF4.13 Billion ≈ $5.23 Billion |
-0.24% |
| 2021-12-31 | CHF4.14 Billion ≈ $5.24 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Galderma Group N's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 635480675000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CHF5.68 Billion | 72.86% |
| Common Stock | CHF3.00 Million | 0.04% |
| Other Comprehensive Income | CHF-6.34 Million | -0.08% |
| Other Components | CHF2.12 Billion | 27.18% |
| Total Equity | CHF7.79 Billion | 100.00% |
Galderma Group N Competitors by Market Cap
The table below lists competitors of Galderma Group N ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shaanxi Coal Industry Co Ltd
SHG:601225
|
$37.07 Billion |
|
KOMATSU LTD. SPONS. ADR 1
F:KOMA
|
$37.13 Billion |
|
China Pacific Insurance Group Co Ltd
SHG:601601
|
$37.29 Billion |
|
People's Insurance of China Ltd
SHG:601319
|
$37.30 Billion |
|
WEG S.A
SA:WEGE3
|
$36.93 Billion |
|
PT BK CE.AS.ADR/25 RP625
F:BZG
|
$36.90 Billion |
|
UltraTech Cement Limited
NSE:ULTRACEMCO
|
$36.85 Billion |
|
Commerzbank AG
F:ZZMS
|
$36.76 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galderma Group N's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,516,094,952 to 7,790,000,000, a change of 3,273,905,048 (72.5%).
- Net income of 231,000,000 contributed positively to equity growth.
- Share repurchases of 13,210,013 reduced equity.
- New share issuances of 2,166,000,000 increased equity.
- Other comprehensive income decreased equity by 15,517,734.
- Other factors increased equity by 905,632,795.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF231.00 Million | +2.97% |
| Share Repurchases | CHF13.21 Million | -0.17% |
| Share Issuances | CHF2.17 Billion | +27.8% |
| Other Comprehensive Income | CHF-15.52 Million | -0.2% |
| Other Changes | CHF905.63 Million | +11.63% |
| Total Change | CHF- | 72.49% |
Book Value vs Market Value Analysis
This analysis compares Galderma Group N's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.39x to 5.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CHF17.45 | CHF163.80 | x |
| 2022-12-31 | CHF17.40 | CHF163.80 | x |
| 2023-12-31 | CHF19.01 | CHF163.80 | x |
| 2024-12-31 | CHF32.78 | CHF163.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galderma Group N utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.20%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.62x
- Recent ROE (2.97%) is above the historical average (-0.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -3.40% | -4.52% | 0.27x | 2.76x | CHF-555.51 Million |
| 2022 | -2.28% | -2.62% | 0.31x | 2.78x | CHF-507.52 Million |
| 2023 | -1.07% | -1.31% | 0.35x | 2.32x | CHF-499.72 Million |
| 2024 | 2.97% | 5.20% | 0.35x | 1.62x | CHF-548.00 Million |
Industry Comparison
This section compares Galderma Group N's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,917,748,962
- Average return on equity (ROE) among peers: 1.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galderma Group N (GALD) | CHF7.73 Billion | -3.40% | 0.67x | $37.01 Billion |
| CURATIS N AG (CURN) | $55.33 Million | -27.15% | 0.25x | $89.64 Million |
| PolyPeptide Group AG (PPGN) | $421.17 Million | 11.22% | 0.41x | $810.06 Million |
| Sandoz Group AG (SDZ) | $6.83 Billion | 5.99% | 1.32x | $29.43 Billion |
| Siegfried Holding Ltd (SFZN) | $367.74 Million | 15.28% | 0.61x | $3.71 Billion |
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more